Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.
Aguirre C, Alonso-Torres A, Agüera E, García-Domínguez JM, Montero-Escribano P, González-Quintanilla V, Costa-Frossard L, Oreja-Guevara C, Reyes-Garrido V, Caminero-Rodríguez AB, Riancho J, Sánchez O, Forero L, Pérez-Parra F, Ares-Luque A, Téllez N, Arzalluz-Luque J, Iglesias F, Casado-Ruiz V, Castellano-Vicente AJ, Borrega L, Galán V, de Antonio LAR, Romero C, García-Rodríguez R, Cano-Orgaz AT, Sánchez-Menoyo JL, Pérez-Ruiz D, Gutiérrez-Martin F, Hernández-Echevarría L, Meca-Lallana V. Aguirre C, et al. Among authors: gonzalez quintanilla v. Clin Drug Investig. 2024 Nov;44(11):829-838. doi: 10.1007/s40261-024-01397-5. Epub 2024 Oct 28. Clin Drug Investig. 2024. PMID: 39466585
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: gonzalez quintanilla v. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study.
Navarro-Pérez MP, González-Quintanilla V, Muñoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, Molina F, Monzón MJ, Medrano V, García-Azorín D, González-Oria C, Gago-Veiga A, Velasco F, Beltrán I, Morollón N, Viguera J, Casas-Limón J, Rodríguez-Vico J, Cuadrado E, Irimia P, Iglesias F, Guerrero-Peral ÁL, Belvís R, Pozo-Rosich P, Pascual J, Santos-Lasaosa S. Navarro-Pérez MP, et al. Among authors: gonzalez quintanilla v. Front Neurol. 2024 Jun 13;15:1417831. doi: 10.3389/fneur.2024.1417831. eCollection 2024. Front Neurol. 2024. PMID: 38938776 Free PMC article.
Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study.
Pascual-Mato M, Gárate G, González-Quintanilla V, Madera-Fernández J, Castro B, García MJ, Crespo J, Rivero M, Pascual J. Pascual-Mato M, et al. Among authors: gonzalez quintanilla v. Headache. 2024 Jul-Aug;64(7):849-858. doi: 10.1111/head.14768. Epub 2024 Jun 24. Headache. 2024. PMID: 38922858
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P; EUREkA study group. Caronna E, et al. J Neurol Neurosurg Psychiatry. 2024 Sep 17;95(10):927-937. doi: 10.1136/jnnp-2023-333295. J Neurol Neurosurg Psychiatry. 2024. PMID: 38777579
48 results